Holen Sie sich die Stockscreener-App
7.895
9.70%
0.675
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - Caledonian Record
IBRX Stock Climbs As ANKTIVA Franchise Momentum Builds - timothysykes.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. LawsuitIBRX - PR Newswire
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - The Joplin Globe
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman - PR Newswire
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE TOMORROW: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS - marketscreener.com
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
IBRX DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ImmunityBio, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
IBRX stock jumps overnight after major FDA review win for Anktiva in bladder cancer - MSN
ImmunityBio secures five US patents for Anktiva in bladder cancer - MSN
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX stock slips overnight: Founder teases Turkey push, says AI cancer cell robot is ‘almost there’ - MSN
IBRX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - TMX Newsfile
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS – Company AnnouncementFT.com - Financial Times
symbol__ Stock Quote Price and Forecast - CNN
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. ... - Caledonian Record
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc.IBRX - lincolnjournal.com
IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar - GlobeNewswire
IBRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C. - Toronto Star
IBRX says ANKTIVA delivers up to $314K cost advantage over J&J's TAR-200 — everything to know about ImmunityBio’s findings - MSN
ImmunityBio presents UK bladder cancer patient survey data By Investing.com - Investing.com South Africa
Final IBRX Deadline Reminder: May 26, 2026 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - PR Newswire
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer - Stocktwits
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with N - pharmiweb.com
IBRX Says ANKTIVA Delivers Up To $314K Cost Advantage Over J&J's TAR-200 — Everything To Know About ImmunityBio’s Findings - Yahoo Finance
ImmunityBio reports cost analysis for bladder cancer treatment - Investing.com
ImmunityBio presents UK bladder cancer patient survey data - Investing.com
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation - Business Wire
TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) - GlobeNewswire
IBRX Stock Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRGRD Law – Company AnnouncementFT.com - Financial Times
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - TMX Newsfile
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX Stock Drops As FDA Warning Triggers Class Actions - timothysykes.com
Tamar Securities Financial PortalImmunityBio, Inc.Common Stock (Nasdaq:IBRX) Stock Quote - FinancialContent
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ... - Caledonian Record
IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - Morningstar
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — HBSS - Morningstar
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ImmunityBio stock (US45258J1025): FDA accepts ANKTIVA bladder cancer filing and sets 2027 PDUFA date - AD HOC NEWS
IBRX 6-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman - marketscreener.com
Assessing ImmunityBio (IBRX) Valuation After FDA Approval For Anktiva And Share Price Cooldown - Yahoo Finance
ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout - Seeking Alpha
ImmunityBio stock surges as FDA accepts bladder cancer filing - Investing.com
Why ImmunityBio Stock is Soaring Higher Today - Yahoo Finance
FDA Accepts IBRX's Filing Seeking Expanded Use of Bladder Cancer Therapy - The Globe and Mail
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Movin - Benzinga
ImmunityBio’s FDA Deadline Could Change Its Bladder-Cancer Story—But the Risk Is Still There - TechStock²
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, - GlobeNewswire
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):